Literature DB >> 2985373

Antilipolytic action of insulin: role of cAMP phosphodiesterase activation.

M L Elks, V C Manganiello.   

Abstract

Exposure of 3T3-L1 adipocytes to 1 nM insulin for 10 min results in activation of particulate cAMP phosphodiesterase and suppression of lipolysis stimulated by 10 nM isoproterenol. When lipolysis was increased by cilostamide, a selective inhibitor of the particulate phosphodiesterase, the antilipolytic effect of insulin was not observed. Insulin did suppress lipolysis stimulated by Ro 20-1724, an inhibitor of soluble cAMP phosphodiesterase activity. Cilostamide did not interfere with insulin stimulation of glucose uptake, nor did it have any direct effect on cAMP-dependent protein kinase. Thus, inhibition of particulate but not soluble cAMP phosphodiesterase blocked the antilipolytic effect of insulin. Our findings support the idea that insulin inhibits lipolysis, perhaps in large part by activating particulate "low Km" cAMP phosphodiesterase, which seems to be functionally closely coupled with the hormone-sensitive lipase-regulatory system influencing primarily a pool of cAMP utilized by the relevant protein kinase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2985373     DOI: 10.1210/endo-116-5-2119

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Gastric inhibitory peptide controls adipose insulin sensitivity via activation of cAMP-response element-binding protein and p110β isoform of phosphatidylinositol 3-kinase.

Authors:  Sameer Mohammad; Lavoisier S Ramos; Jochen Buck; Lonny R Levin; Francesco Rubino; Timothy E McGraw
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

2.  Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents.

Authors:  C H Macphee; S A Harrison; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

3.  Specific inhibition of the cGMP-inhibited cAMP phosphodiesterase blocks the insulin-like antilipolytic effect of growth hormone in rat adipocytes.

Authors:  H Eriksson; H Tornqvist
Journal:  Mol Cell Biochem       Date:  1997-04       Impact factor: 3.396

4.  Counter-regulation by insulin and isoprenaline of a prominent fat-associated phosphoprotein doublet in rat adipocytes.

Authors:  R A Mooney; K L Bordwell
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

5.  Expression and regulation of cyclic nucleotide phosphodiesterases in human and rat pancreatic islets.

Authors:  Emilia Heimann; Helena A Jones; Svante Resjö; Vincent C Manganiello; Lena Stenson; Eva Degerman
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

Review 6.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

7.  Insulin stimulates interleukin-6 expression and release in LS14 human adipocytes through multiple signaling pathways.

Authors:  Christopher R LaPensee; Eric R Hugo; Nira Ben-Jonathan
Journal:  Endocrinology       Date:  2008-07-10       Impact factor: 4.736

8.  Comparison of voglibose and nateglinide for their acute effects on insulin secretion and free fatty acid levels in OLETF rat portal blood after sucrose loading.

Authors:  Yutaka Mori; Yoshirou Kitahara; Kyouko Miura; Naoko Tajima
Journal:  Endocrine       Date:  2004-02       Impact factor: 3.633

9.  Amino acid-sensing mTOR signaling is involved in modulation of lipolysis by chronic insulin treatment in adipocytes.

Authors:  Chongben Zhang; Mee-Sup Yoon; Jie Chen
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-02-03       Impact factor: 4.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.